Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
03:19pm, Monday, 18'th Apr 2022 Benzinga
Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, whi
Biogen's new Alzheimer's drug could boost the stock by 60%, says Wells Fargo's Mohit Bansal
02:21pm, Monday, 18'th Apr 2022
Mohit Bansal, Wells Fargo Securities senior equity analyst, joins 'The Exchange to discuss drug company Biogen and what its new Alzheimer's drug could mean to the stock.
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
02:04pm, Monday, 18'th Apr 2022 Benzinga
Upgrades
For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q
Biogen Inc. (BIIB) Stock Moves -0.67%: What You Should Know
10:00pm, Thursday, 14'th Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $212.55, marking a -0.67% move from the previous day.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
07:38pm, Thursday, 14'th Apr 2022 Zacks Investment Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
3 Biotech Stocks That Could Help Make You a Fortune
10:00am, Thursday, 14'th Apr 2022 The Motley Fool
Their products could deliver major revenue over time.
Biogen's Aduhelm Crashes the Biotech Sector
07:36am, Wednesday, 13'th Apr 2022
Aduhelm is an Alzheimer's treatment, not a cure. Its quick approval and high price have set off pushback on the whole FDA and Medicare drug process.
U.S. stocks end mostly lower, with Dow, S&P 500 Nasdaq sliding for the week as investors digest Fed plans amid rising yields
12:33am, Saturday, 09'th Apr 2022 MarketWatch
U.S. stock benchmarks end mostly lower Friday, with the technology-laden Nasdaq Composite and S&P 500 closing down, as investors continue to digest the Federal Reserve's commentary on interest rates w
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
09:50pm, Friday, 08'th Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $214.75, marking a +1.47% move from the previous day.
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
05:02pm, Friday, 08'th Apr 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
12:59pm, Friday, 08'th Apr 2022 Zacks Investment Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
10:32am, Friday, 08'th Apr 2022
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Why Is Biogen (BIIB) Stock in the Spotlight Today?
10:01am, Friday, 08'th Apr 2022
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today. The post Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare Will Limit Coverage of Biogen's Alzheimer's Drug to Those in Clinical Trials
10:42pm, Thursday, 07'th Apr 2022
The Centers for Medicare and Medicaid Services on Thursday confirmed it will limit routine payment for Biogen's Aduhelm--designed to treat early-stage Alzheimer's disease--to patients enrolled in appr
Biogen stock edges lower after Medicare restrictions on Aduhelm finalized
05:21pm, Thursday, 07'th Apr 2022
Shares of Biogen Inc. BIIB, +0.92% fell 0.3% in the extended session Thursday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said they had finalized their p
